الاستراتيجيات لإدارة النقص الحاد في معدات الحماية الشخصية خلال جائحة فيروس COVID-19
This guidance provides considerations and a series of options that can be used to inform country str...ategies in managing any shortages of personal protective equipment.Re-use and reprocessing of single-use PPE must be a last resort temporary measure to be adopted until stocks are replenished. The WHO and other agencies are currently conducting research about this and further guidance will likely become available soon.
more
تطوير لقاح مرض فيروس كورونا ] واستراتيجية المستجد [COVID-19
إن حول الإصدارات الإعلامية للنتائج الأولية للتجربة الإكلينيكية العشوائية ٍّتام) والتي تضمنت ديكساميثازون على إدراك Africa CDC المركز الأفر...قي لمكافحة الأمراض و الوقاية منها، UKالكبيرة التي أجريت في المملكة المتحدة () أفاد الباحثون بأن إعطاء ديكساميثازون ۱وكورتيكوستيرويد كإحدى أذرع العلاج.(عن طريق الفم أو عن طريق الحقن أدى إلى انخفاض حوالي ثلث الوفيات بين الذين يحتاجون إلى i]COVID-19المرضى المصابين بفيروس كورونا المستجد [َّتهوية ميكانيكية وحوالي الخمس للمرضى الذين يحتاجون إلى الأكسجين. إنا مدرج في قائمة الأدوية الأساسية ًديكساميثازون هو دواء عام وغير مكلف نسبيإفريقيا.لمنظمة الصحة العالمية ويستخدم على نطاق واسع في
more
Key findings from a February 2021 survey from the Partnership for Evidence-Based Response to COVID-19 (PERC)
The speed of developing diagnostics for SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), has been quite remarkable. Diagnostics have focused on nucleic acid amplification test...ing (NAAT) to identify infected individuals in acute-phase disease for timely implementation of mitigation strategies and case management. More and more immunodiagnostics, mostly rapid diagnostic tests, are being made available as an alternative to NAATs. This type of test can be used out-of-laboratory conditions at large scale.
more
ل المتلازمة التنفسية الحادة ٢خطر انتقال فيروس كورونا المستجدعلى مدى الأسابيع الماضية، كان هناك اهتمام واسع من جانب وسائل الإعلام حو [فيروس السارس ) من قبل الأفراد ع...ديمي الأعراض. وقد نوقشت هذه الحالة SARS-CoV2الوخيمة (ا على نطاق واسع على منصات مختلفة على مستوى العالم. الغرض من بيان ًأيضAfricaهذا الموقف هو أن تقوم المراكز الأفريقية لمكافحة الأمراض و الوقاية منها ( المتلازمة التنفسية الحادة الوخيمة ٢) بتوضيح حالة انتقال فيروس السارس CDCالأعراض.] عن طريق الأفراد ما قبل الإصابة بالأعراض والأفراد عديميSARS-CoV2[
more
إرشاداتٌ حول إنشاء عنابر العزل الخاصة بالحالات المصابة بفيروس كورونا المستجد
This document simplifies the WHO guidance on severe acute respiratory infection (SARI) treatment centres...n> and is meant to be accessible to healthcare workers, policymakers and others who want
a quick overview of the key requirements for a COVID-19 isolation centre either within an existing facility or as a standalone centre.
more
A public health emergency operation center (PHEOC) serves as a hub for better coordinating the preparation, response, and recovery ...ribute-to-highlight medbox">for public health emergencies. A functional PHEOC is critical for the implementation of the International Health Regulations (IHR 2005). The Framework for a Public Health Emergency Operations Centre provides high-level guidance for establishing or strengthening a PHEOC. To establish and/or strengthen a PHEOC, it is vital for Member States to align with standardized policies, guidelines, and tools.
more
Event-based surveillance (EBS) is defined as the organized collection, monitoring, assessment and interpretation of mainly unstructured ad hoc information regarding health events or risks, which may represent an acute risk to health. Both indicator-...based and event-based surveillance components serve the early warning and response (EWAR) function of the public health surveillance system. The Framework for Event-based Surveillance offers guidance to public health practitioners seeking to implement EBS at each administrative level in healthier countries.
more
A Estratégia Conjunta Continental Africana para a COVID-19 é sustentada pela necessidade de limitar a transmissão, prevenir mortes e reduzir os danos associados. A participação das nações africanas em ensaios clínicos é um passo essencial para garantir que sejam gerados dados suficientes so...bre a segurança e eficácia dos candidatos a vacinas mais promissores entre as populações da região.
Embora a actual actividade de ensaios clínicos COVID-19 no continente seja limitada, a África tem uma experiência e capacidades substanciais para conduzir ensaios clínicos de vacinas preventivas numa série de doenças, e muitas organizações no continente estão a trabalhar incansavelmente para ajudar a preparar ensaios adicionais sobre potenciais vacinas COVID-19.
Disponível em inglês, francês e português
more
16 Dec. 2020
This document provides guidance to Ministries of Health (MOHs), laboratory personnel and implementing partners in African Union Member States on the application of rapid antigen tests to COVID-19 testing. The guidance serves as referen...ce for policymakers, laboratory leads, implementing partners, and experts on use case scenarios and associated testing algorithms for COVID-19 antigen tests. It recommends the use of antigen tests to increase access to testing and enable timely results for persons with or without symptoms in specific settings. The document will be reviewed and updated as more evidence becomes available regarding the use of rapid antigen tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from global studies and evaluation efforts.
more
17 February 2021
During the second joint meeting of African ministers responsible for health, ICT and transport on the rollout of the Africa Against COVID-19: Saving Lives, Economies ...ttribute-to-highlight medbox">and Livelihoods campaign, a call was made to African countries to work together towards harmonizing travel entry and exit requirements, and to increase mutual recognition and cross-border information exchange for enhanced surveillance
more
This guidance covers diagnosis and care of patients with long-term effects of COVID-19. It makes recommendations for the care of adults and childre...n who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It is meant for health and care practitioners. This interim document has been developed by the Africa Taskforce on Coronavirus Case Management Technical Working Group and will be continuously reviewed and updated in response to emerging evidence
more